Education
About Us
Working with TipRanks
Follow Us
Senti Biosciences (SNTI)
NASDAQ:SNTI
SNTI Stock Chart & Stats
$2.13
-$0.36(-8.15%)
At close: 4:00 PM EST
$2.13
-$0.36(-8.15%)
Day’s Range― - ―
52-Week Range$1.26 - $7.10
Previous CloseN/A
Volume20.15K
Average Volume (3M)260.00K
Market Cap
$58.37M
Enterprise Value$64.77M
Total Cash (Recent Filing)$12.24M
Total Debt (Recent Filing)$30.12M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding26,290,838
10 Day Avg. Volume505,690
30 Day Avg. Volume260,000
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.39
Enterprise Value/Market Cap1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.87
Enterprise Value/Ebitda-1.45
Forecast
1Y Price Target
$10.00Price Target Upside369.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSenti’s lead clinical candidate, SENTI-202, is an elegantly designed allogeneic, or off-the-shelf, CAR-NK cell therapy in Ph 1 for relapsed or refractory acute myeloid leukemia—a notoriously treatment-refractory malignancy.
Safety ProfileSENTI-202 has been well tolerated with no dose-limiting toxicities (DLTs) or severe treatment-related adverse events (TEAEs).
Therapeutic InnovationsSenti’s novel Logic-Gated gene circuit platform offers a promising solution to solve the therapeutic window problem that has plagued cell therapies pursuing cancers with 'dirty' antigen targets.
Bears Say
Response Rate DeclineThe updated overall response rate (ORR) for SENTI-202 decreased to 50% from a previous 71%.
Senti Biosciences News
SNTI FAQ
What was Senti Biosciences’s price range in the past 12 months?
Senti Biosciences lowest stock price was $1.26 and its highest was $7.10 in the past 12 months.
What is Senti Biosciences’s market cap?
Senti Biosciences’s market cap is $58.37M.
When is Senti Biosciences’s upcoming earnings report date?
Senti Biosciences’s upcoming earnings report date is May 12, 2026 which is in 155 days.
How were Senti Biosciences’s earnings last quarter?
Senti Biosciences released its earnings results on Nov 13, 2025. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.567 by -$0.123.
Is Senti Biosciences overvalued?
According to Wall Street analysts Senti Biosciences’s price is currently Undervalued.
Does Senti Biosciences pay dividends?
Senti Biosciences does not currently pay dividends.
What is Senti Biosciences’s EPS estimate?
Senti Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senti Biosciences have?
Senti Biosciences has 26,290,838 shares outstanding.
What happened to Senti Biosciences’s price movement after its last earnings report?
Senti Biosciences reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.567. Following the earnings report the stock price went down -10.056%.
Which hedge fund is a major shareholder of Senti Biosciences?
Currently, no hedge funds are holding shares in SNTI
Senti Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (369.48% Upside)
$10.00 (369.48% Upside)
Hedge Fund Trend
Decreased
By 28.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
-394.62%
Trailing 12-Months
Asset Growth
-21.14%
Trailing 12-Months
Company Description
Senti Biosciences
Senti Biosciences (SNTI) is a biotechnology company that focuses on the development of next-generation cell and gene therapies. The company leverages synthetic biology to create advanced therapeutic solutions aimed at treating complex diseases, particularly in the areas of oncology and genetic disorders. Senti's core products include engineered cell therapies that are designed to be more precise, potent, and controllable than traditional approaches.
SNTI Stock 12 Month Forecast
Average Price Target
$10.00
▲(369.48% Upside)
Technical Analysis
Plus Therapeutics
―
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
IO Biotech
―
Ownership Overview
65.85% Insiders
1.91% Mutual Funds
17.74% Other Institutional Investors
12.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---